N Sacks
- Cancer Research top 2%
- Breast Cancer Treatment Studies 7
- Oncology top 5%
- HER2/EGFR in Cancer Research 8
- Cancer Treatment and Pharmacology 4
- Genetics top 5%
- Estrogen and related hormone effects 4
- BRCA gene mutations in cancer 3
-
- Monoclonal and Polyclonal Antibodies Research 8
- Radiopharmaceutical Chemistry and Applications 2
-
- Glycosylation and Glycoproteins Research 2
- Partner nations
- United KingdomAustraliaUnited States
In The Last Decade
N Sacks
27 papers receiving 1.8k citations
Peers
Comparison fields: 5 of 103
- Cancer Research 792
- Oncology 976
- Pathology and Forensic Medicine 390
- Genetics 551
- Pulmonary and Respiratory Medicine 346
Countries citing papers authored by N Sacks
This map shows the geographic impact of N Sacks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N Sacks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N Sacks more than expected).
Fields of papers citing papers by N Sacks
This network shows the impact of papers produced by N Sacks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N Sacks. The network helps show where N Sacks may publish in the future.
Co-authorship network
The 25 scholars most cited alongside N Sacks, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2003 | 71 | |
| 2 | 2003 | 10 | |
| 3 | 2002 | 123 | |
| 4 | HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. | 2001 | 150 |
| 5 | 2000 | 60 | |
| 6 | 1999 | 43 | |
| 7 | 1998 | 98 | |
| 8 | 1998 | 33 | |
| 9 | 1997 | 140 | |
| 10 | 1995 | 267 | |
| 11 | 1995 | 11 | |
| 12 | 1995 | 150 | |
| 13 | 1995 | 10 | |
| 14 | 1994 | 31 | |
| 15 | 1994 | 117 | |
| 16 | 1993 | 15 | |
| 17 | 1993 | 4 | |
| 18 | 1993 | 65 | |
| 19 | 1989 | 31 | |
| 20 | 1987 | 37 |
About N Sacks
N Sacks is a scholar working on Cancer Research, Oncology, Radiology, Nuclear Medicine and Imaging, Internal Medicine and Genetics, having authored 28 papers that have together received 1.8k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (8 papers), Monoclonal and Polyclonal Antibodies Research (8 papers), Breast Cancer Treatment Studies (7 papers), Cancer Treatment and Pharmacology (4 papers), Estrogen and related hormone effects (4 papers), BRCA gene mutations in cancer (3 papers), Glycosylation and Glycoproteins Research (2 papers) and Radiopharmaceutical Chemistry and Applications (2 papers). The work is most often cited by research in Cancer Research (792 citations), Oncology (976 citations), Pathology and Forensic Medicine (390 citations), Genetics (551 citations) and Pulmonary and Respiratory Medicine (346 citations). N Sacks has collaborated with scholars based in United Kingdom, Australia and United States. Frequent co-authors include Mitch Dowsett, A G Nash, S. Ashley, Tamas Hickish, Mary O’Brien, T.J. Powles, S. Ebbs, Giles Davies, Lesley‐Ann Martin and G. Walsh. Their work appears in journals such as British Journal of Cancer, The Breast, Annals of Oncology, Journal of Clinical Oncology and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.